The potential applications of Apolipoprotein E in personalized medicine
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Personalized medicine uses various individual characteristics to guide medical decisions. Apolipoprotein (ApoE), the most studied polymorphism in humans, has been associated with several diseases. The purpose of this review is to elucidate the potential role of ApoE polymorphisms in personalized medicine, with a specific focus on neurodegenerative diseases, by giving an overview of its influence on disease risk assessment, diagnosis, prognosis, and therapy. This review is not a systematic inventory of the literature, but rather a summary and discussion of novel, influential and promising works in the field of ApoE research that could be valuable for personalized medicine. Empirical evidence suggests that ApoE genotype informs pre-symptomatic risk for a wide variety of diseases, is valuable for the diagnosis of type III dysbetalipoproteinemia, increases risk of dementia in neurodegenerative diseases, and is associated with a poor prognosis following acute brain damage. ApoE status appears to influence the efficacy of certain drugs, outcome of clinical trials, and might also give insight into disease prevention. Assessing ApoE genotype might therefore help to guide medical decisions in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 2×
“This duality found in the ApoE2 isoform suggests that the adverse or beneficial impact of ApoE2, and potentially ApoE4, on disease risk is influenced by it interaction with other genetic or environmental factors (Lahoz et al., 2001; Elosua et al., 2003; Mahley et al., 2009).”
BackgroundNeurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 2×
“…risk factor for late onset Alzheimer Disease (AD) (Poirier et al., 1993; Leduc et al., 2011; Verghese et al., 2011) with ApoE4 carriers having a 4 to 12-fold increased risk of developing AD when compared to non-carriers (Corder et al., 1993, 1994; Bertram and Tanzi, 2008; Mahley and Huang, 2012a).”
BackgroundVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 5×
“In the brain, cholesterol plays a crucial role in myelin production and is an essential component of membrane sheaths, brain development, neuronal maintenance, neuronal repair, and long-term synaptic plasticity (Mauch et al., 2001; Bu, 2009; Mahley et al., 2009; Leduc et al., 2011).”
BackgroundInfluentialCNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 2×
“…is also associated with greater neuronal inflammation (Grainger et al., 2004; Guo et al., 2004; Kim et al., 2009; Leduc et al., 2011) and less efficient neuronal repair (Mauch et al., 2001; Bu, 2009; Mahley et al., 2009; Leduc et al., 2011), two other conditions that might influence the risk of AD.”
BackgroundThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“ApoE4 is also associated with greater neuronal inflammation (Grainger et al., 2004; Guo et al., 2004; Kim et al., 2009; Leduc et al., 2011) and less efficient neuronal repair (Mauch et al., 2001; Bu, 2009; Mahley et al., 2009; Leduc et al., 2011), two other conditions that might influence the risk…”
BackgroundApolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 1×
“While several routes exist for the clearance of Aβ, clearance directly into the blood seems to be the predominant pathway in the human brain (Bell and Zlokovic, 2009; Bell et al., 2012).”
BackgroundApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Apolipoprotein E polymorphism and Alzheimer's disease
Poirier, J., Bertrand, P., Poirier, J., Kogan, S., Gauthier, S., Poirier, J., Gauthier, S., Davignon, J., Bouthillier, D., & Davignon, J. (1993) · The Lancet · doi:10.1016/0140-6736(93)91705-q · Cited by 1,108
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 8×
“…in 1973 (Shore and Shore, 1973), ApoE has become one of the most widely studied gene variants, not only for cardiovascular disorders but also in relation to several other medical conditions such as neurodegenerative and autoimmune diseases (Mahley, 1988; Mahley et al., 2009; Verghese et al., 2011).”
BackgroundInfluentialAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796 · cited 3×
“…essential to maintain the structural integrity of lipoproteins, stabilize, and solubilize Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 154 | 1 AGING NEUROSCIENCE liproproteins in the blood, and to serve as cofactors in enzymatic reaction (Eichner et al., 2002).”
BackgroundAssociation of apolipoprotein E genotypes with lipid levels and coronary risk
Bennet, A. M., Di Angelantonio, E., Ye, Z., Wensley, F., Dahlin, A., Ahlbom, A., Keavney, B., Collins, R., Wiman, B., de Faire, U., et al. (2007) · JAMA · doi:10.1001/jama.298.11.1300 · Cited by 794
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 2×
“In the same line, ApoE4 is associated with slower transport of Aβ across the blood-brain barrier (BBB), causing greater Aβ retention in mice brains (Deane et al., 2008).”
BackgroundThirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
Bertram, L., & Tanzi, R. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2494 · Cited by 747 · cited 1×
“…risk factor for late onset Alzheimer Disease (AD) (Poirier et al., 1993; Leduc et al., 2011; Verghese et al., 2011) with ApoE4 carriers having a 4 to 12-fold increased risk of developing AD when compared to non-carriers (Corder et al., 1993, 1994; Bertram and Tanzi, 2008; Mahley and Huang, 2012a).”
BackgroundRisner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Apolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 1×
“In the brain, ApoE is produced by astrocytes and, to a minor extent, by microglia (Pitas et al., 1987; Grehan et al., 2001), and can also be produced by neurons in response to neuronal injury or stress (Mahley and Huang, 2012a).”
BackgroundApolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS
Mahley, R. W., Weisgraber, K. H., & Huang, Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800069-jlr200 · Cited by 580
Isoform-specific binding of apolipoprotein E to beta-amyloid.
LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G. S., & Frail, D. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31529-6 · Cited by 540
Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease
Song, Y., Stampfer, M. J., & Liu, S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-2-200407200-00013 · Cited by 528 · cited 2×
“E4 CARDIOVASCULAR DISEASES (Lahoz et al., 2001; Eichner et al., 2002; Masson et al., 2003; Song et al., 2004; Martinez-Gonzalez and Sudlow, 2006; Stehle et al., 2008; Mahley et al., 2009; Guo et al., 2011; Khan et al., 2013; Rannikmae et al., 2013)”
BackgroundMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Apolipoprotein e sets the stage: response to injury triggers neuropathology
Mahley, R. W., & Huang, Y. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.020 · Cited by 412
Carrière, I., Fourrier-Reglat, A., Dartigues, J.-F., Rouaud, O., Pasquier, F., Ritchie, K., & Ancelin, M.-L. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.229 · Cited by 374
Dong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H., & Agard, D. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31797-0 · Cited by 320
Human Apolipoprotein E4 Domain Interaction
Dong, L.-M., & Weisgraber, K. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19053 · Cited by 318
Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., & Mahley, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508693102 · Cited by 275
TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267 · cited 1×
“E4 CARDIOVASCULAR DISEASES (Lahoz et al., 2001; Eichner et al., 2002; Masson et al., 2003; Song et al., 2004; Martinez-Gonzalez and Sudlow, 2006; Stehle et al., 2008; Mahley et al., 2009; Guo et al., 2011; Khan et al., 2013; Rannikmae et al., 2013)”
Self-citationEffect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e8d0 · Cited by 248 · cited 1×
“…mechanism is via accumulation and/or clearance of amyloid-β (Aβ, a hallmark of AD) from the brain because ApoE4 has been associated with greater Aβ burden (Strittmatter et al., 1993; Ye et al., 2005; Drzezga et al., 2009) and ApoE2 with lower Aβ burden (Jiang et al., 2008; Morris et al., 2010).”
BackgroundLalazar (1989) · doi:10.1016/s0021-9258(18)81806-3 · Cited by 238
Song, F., Poljak, A., Crawford, J., Kochan, N. A., Wen, W., Cameron, B., Lux, O., Brodaty, H., Mather, K., Smythe, G. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034078 · Cited by 214 · cited 2×
“Higher cerebrospinal fluid (CSF) ApoE levels have also been associated with higher cognitive impairment in patients affected by HIV (Andres et al., 2011), a finding that was also present in persons with mild cognitive impairment (Song et al., 2012) but not in AD patients (Schmidt et al., 2014).”
BackgroundAPOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins, C. A. R., Oulhaj, A., de Jager, C. A., & Williams, J. H. (2005) · Neurology · doi:10.1212/01.wnl.0000188871.74093.12 · Cited by 205
Grainger, D. J., Reckless, J., & McKilligin, E. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.6366 · Cited by 183
A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity
Guo, L., LaDu, M. J., & Van Eldik, L. J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:205 · Cited by 175
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152 · cited 1×
“While some studies suggest that ApoE4 AD carriers have a faster rate of cognitive decline (Craft et al., 1998; Martins et al., 2005; Schmidt et al., 2012), others suggest no association (Growdon et al., 1996; Kleiman et al., 2006).”
BackgroundGrehan, S., Tse, E., & Taylor, J. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00812.2001 · Cited by 138
Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132
Ponsford, J., McLaren, A., Schönberger, M., Burke, R., Rudzki, D., Olver, J., & Ponsford, M. (2011) · Journal of Neurotrauma · doi:10.1089/neu.2010.1623 · Cited by 103
Apolipoprotein E-genotype dependent hippocampal and cortical responses to traumatic brain injury
Crawford, F., Wood, M., Ferguson, S., Mathura, V., Gupta, P., Humphrey, J., Mouzon, B., Laporte, V., Margenthaler, E., O'Steen, B., et al. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.01.033 · Cited by 59
Cited by
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Marais, A. D. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.002 · Cited by 382
Rabin, J. S., Schultz, A. P., Hedden, T., Viswanathan, A., Marshall, G. A., Kilpatrick, E., Klein, H., Buckley, R. F., Yang, H.-S., Properzi, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1123 · Cited by 221
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Tung, M.-C., Lan, Y.-W., Li, H.-H., Chen, H.-L., Chen, S.-Y., Chen, Y.-H., Lin, C.-C., Tu, M.-Y., & Chen, C.-M. (2020) · Scientific Reports · doi:10.1038/s41598-020-65782-8 · Cited by 57
Karjalainen, J.-P., Mononen, N., Hutri-Kähönen, N., Lehtimäki, M., Juonala, M., Ala-Korpela, M., Kähönen, M., Raitakari, O., & Lehtimäki, T. (2019) · Scientific Reports · doi:10.1038/s41598-018-36450-9 · Cited by 55
Metadata
- Authors
- Villeneuve, S., Brisson, D., Marchant, N. L., & Gaudet, D.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-07-08
- Volume
- 6
- Pages
- 154-154
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2080546486
- Cited by
- 48
- References
- 42
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.